logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Sectors
RLAY
Relay Therapeutics, Inc.
18.82
1 x 18.80
2 x 18.87
bid
ask
-
0.02
0.08%
10:06 AM
timesize
Ytd122.52%
1y303.97%
18.51
day range
19.17
4.32
52 week range
21.27
Open19.07Prev Close18.84Low18.51High19.17Mkt Cap4.10B
Vol191.92KAvg Vol3.18MEPS-1.56P/EN/AForward P/E-11.51
Beta1.69Short Ratio18.99Inst. Own110.91%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-0550-d Avg19.32200-d Avg13.491yr Est27.08

RLAY News

Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com
Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference

Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference

Squarepoint Ops LLC Has $1.74 Million Position in Relay Therapeutics, Inc. $RLAY
defenseworld.net
Squarepoint Ops LLC Has $1.74 Million Position in Relay Therapeutics, Inc. $RLAY

Squarepoint Ops LLC lessened its holdings in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) by 48

VIRGINIA RETIREMENT SYSTEMS ET Al Acquires New Stake in Relay Therapeutics, Inc. $RLAY
defenseworld.net
VIRGINIA RETIREMENT SYSTEMS ET Al Acquires New Stake in Relay Therapeutics, Inc. $RLAY

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Relay Therapeutics, Inc. (NASDA
benzinga.com
HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $29

HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Bu
benzinga.com
JP Morgan Maintains Overweight on Relay Therapeutics, Raises Price Target to $31

JP Morgan analyst Priyanka Grover maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight an
benzinga.com
Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $26

Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperfo
benzinga.com
Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $30

Barclays analyst Etzer Darout maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and ra
benzinga.com
Relay Therapeutics Q2 EPS $(0.41) Misses $(0.39) Estimate, Sales $350.000K Miss $872.727K Estimate

Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.41) per share which missed the ana
benzinga.com
Goldman Sachs Maintains Buy on Relay Therapeutics, Raises Price Target to $31

Goldman Sachs analyst Salveen Richter maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and r
benzinga.com
Canaccord Genuity Initiates Coverage On Relay Therapeutics with Buy Rating, Announces Price Target o

Canaccord Genuity analyst John Newman initiates coverage on Relay Therapeutics (NASDAQ:RLAY) with
benzinga.com
JP Morgan Initiates Coverage On Relay Therapeutics with Overweight Rating, Announces Price Target of

JP Morgan analyst Priyanka Grover initiates coverage on Relay Therapeutics (NASDAQ:RLAY) with a O
benzinga.com
Guggenheim Maintains Buy on Relay Therapeutics, Raises Price Target to $26

Guggenheim analyst Brad Canino maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises t
benzinga.com
HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $28

HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Bu

Advance Auto Parts Posts Upbeat Q1 Earnings, Joins IBM, Ralph Lauren And Other Big Stocks Moving Higher On Thursday
benzinga.com
Advance Auto Parts Posts Upbeat Q1 Earnings, Joins IBM, Ralph Lauren And Other Big Stocks Moving Hig

U.S. stocks were lower on Thursday, with Nasdaq falling over 200 points. Advance Auto Parts Inc (NYS
benzinga.com
Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $27

Barclays analyst Etzer Darout maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and ra
benzinga.com
Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $21

Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperfo

Lowe's, ZTO Express, Viavi Solutions And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
benzinga.com
Lowe's, ZTO Express, Viavi Solutions And Other Big Stocks Moving Lower In Wednesday's Pre-Market Ses

US stock futures higher, Lowe's shares fall after reporting earnings. Other stocks declining in

benzinga.com
Relay Therapeutics Launches $175M Public Stock Offering

Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company

benzinga.com
Raymond James Maintains Strong Buy on Relay Therapeutics, Raises Price Target to $26

Raymond James analyst Dane Leone maintains Relay Therapeutics (NASDAQ:RLAY) with a Strong Buy and

Relay Therapeutics Reports Early Success For Investigational Drug In Rare Vascular Disorders
benzinga.com
Relay Therapeutics Reports Early Success For Investigational Drug In Rare Vascular Disorders

Relay Therapeutics reported early Phase 2 data showing lesion reduction and symptom improvement with
benzinga.com
Relya Therapeutics Announces Initial Clinical Data From The Phase 2 ReInspire Trial Of Zovegalisib I

Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowes
benzinga.com
Relay Therapeutics Q1 EPS $(0.41) Misses $(0.37) Estimate, Sales $3.000M Beat $2.560M Estimate

Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.41) per share which missed the ana

Earnings Scheduled For May 5, 2026
benzinga.com
Earnings Scheduled For May 5, 2026

Starbucks To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Wednesday
benzinga.com
Starbucks To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Wednesday

Analysts change outlook & ratings for QGEN, AWI, CR, ATEN, PLUG, SBUX, CECO, CNC. Price targets

benzinga.com
HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $25

HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Bu
benzinga.com
Goldman Sachs Maintains Buy on Relay Therapeutics, Raises Price Target to $22

Goldman Sachs analyst Salveen Richter maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and r
benzinga.com
Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $19

Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperfo
benzinga.com
Wells Fargo Maintains Overweight on Relay Therapeutics, Raises Price Target to $21

Wells Fargo analyst Eva Fortea Verdejo maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweig
benzinga.com
Oppenheimer Maintains Outperform on Relay Therapeutics, Raises Price Target to $18

Oppenheimer analyst Matthew Biegler maintains Relay Therapeutics (NASDAQ:RLAY) with a Outperform

benzinga.com
Relay Therapeutics Plans To Move Zovegalisib + Atirmociclib, Pfizer's Investigational, CDK4 Inhibito

Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline developmentCompelling effi
benzinga.com
Jones Trading Initiates Coverage On Relay Therapeutics with Hold Rating, Announces Price Target of $

Jones Trading analyst Boris Peaker initiates coverage on Relay Therapeutics (NASDAQ:RLAY) with a

benzinga.com
Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $21

Barclays analyst Etzer Darout maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and ra
benzinga.com
Relay Therapeutics To Present Initial Clinical Results, Preclinical Data For Zovegalisib In Vascular

Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company

12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com
HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $19

HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Bu
benzinga.com
Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $17

Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperfo
benzinga.com
Wells Fargo Maintains Overweight on Relay Therapeutics, Raises Price Target to $17

Wells Fargo analyst Eva Fortea Verdejo maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweig

Relay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free Survival - What Does This Means For Pretreated Breast Cancer Patients?
benzinga.com
Relay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free Survival - What Does This Means For

Relay Therapeutics shares rise after Phase 3 data show zovegalisib achieved 11.1-month PFS in metast
benzinga.com
Guggenheim Maintains Buy on Relay Therapeutics, Raises Price Target to $22

Guggenheim analyst Brad Canino maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises t
benzinga.com
Wells Fargo Maintains Overweight on Relay Therapeutics, Raises Price Target to $15

Wells Fargo analyst Eva Fortea Verdejo maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweig

12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session

Relay Therapeutics Q4 Earnings Assessment
benzinga.com
Relay Therapeutics Q4 Earnings Assessment

Earnings Scheduled For February 26, 2026
benzinga.com
Earnings Scheduled For February 26, 2026

Relay Therapeutics Earnings Preview
benzinga.com
Relay Therapeutics Earnings Preview
benzinga.com
Oppenheimer Upgrades Relay Therapeutics to Outperform, Announces $14 Price Target

Oppenheimer analyst Matthew Biegler upgrades Relay Therapeutics (NASDAQ:RLAY) from Perform to Out

Relay Therapeutics Reports 'Robust Activity' For Precision Breast Cancer Drug
benzinga.com
Relay Therapeutics Reports 'Robust Activity' For Precision Breast Cancer Drug

Relay Therapeutics shared interim data for zovegalisib at SABCS 2025, showing consistent efficacy in
benzinga.com
Wells Fargo Upgrades Relay Therapeutics to Overweight, Raises Price Target to $13

Wells Fargo analyst Eva Fortea Verdejo upgrades Relay Therapeutics (NASDAQ:RLAY) from Equal-Weigh
benzinga.com
Relay Therapeutics Presents Subset Analysis Of Interim Phase 3 Data For Zovegalisib At SABCS 2025

Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all pati

Alibaba, Oscar Health, Ondas Holdings, Lumentum, Tesla And Other Big Stocks Moving Higher On Monday
benzinga.com
Alibaba, Oscar Health, Ondas Holdings, Lumentum, Tesla And Other Big Stocks Moving Higher On Monday
benzinga.com
Wells Fargo Maintains Equal-Weight on Relay Therapeutics, Raises Price Target to $6

Wells Fargo analyst Eva Fortea Verdejo maintains Relay Therapeutics (NASDAQ:RLAY) with a Equal-We